Measuring serum antibody to human papillomavirus following infection or vaccination

Gynecologic Oncology

Volumn 118, Issue 1 SUPPL. 1, 2010, Pages

  Frazer, Ian H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cross protection; Human papillomavirus; Immune marker; Immune memory

Indexed keywords

ALUMINUM HYDROXIDE; CAPSID PROTEIN L1; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; VIRUS ANTIBODY; WART VIRUS VACCINE;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; GOOD CLINICAL PRACTICE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL MEMORY; INFECTION PREVENTION; MEDICAL RESEARCH; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW; RISK ASSESSMENT; SEROLOGY; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VIRUS LIKE AGENT; VIRUS VIRULENCE; WART VIRUS;

ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 77952299521     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.04.003     Document Type: Review

References (26)

1. Stanley M., Lowy D.R., and Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 24 Suppl 3 (2006) S106-S113
2. Trottier H., and Franco E.L. The epidemiology of genital human papillomavirus infection. Vaccine 24 Suppl 1 (2006) S1-15
3. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., and Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 RR-2 (2007) 1-24
4. Chen X.S., Garcia R.L., Goldberg I., Casini G., and Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5 (2000) 557-567
5. Combita A.L., Touzé A., Bousarghin L., Christensen N.D., and Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76 (2002) 6480-6486
6. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
7. Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., Teixeira J.C., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374 (2009) 1975-1985
8. TM (GSK HPV-16/18 ASO4 vaccine). Presented at the 26th Annual Meeting of the European Society for Paediatric Infectious Diseases Conference (2008 May), Graz, Austria 13-17 Abstract
9. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
10. Ault K.A., and Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 369 (2007) 1861-1868
11. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 (2006) 1459-1466
12. Rowhani-Rahbar A., Mao C., Alvarez F.B., Bryan J.T., Hawes S.E., Hughes J.P., et al. Long-term efficacy of a prophylactic human papillomavirus type 16 vaccine. Presented at the 25th International Papillomavirus Conference (2009 May), Malmö, Sweden 8-14 Abstract O-01.03
13. Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 (2009) 301-314
14. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 (2007) 1693-1702
15. Petäjä T., Keränen H., Karppa T., Kawa A., Lantela S., Siitari-Mattila M., et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 44 (2009) 33-40
16. Giuliano A., and Palefsky J. Quadrivalent HPV vaccine efficacy against male genital disease and infection. Presented at the 25th International Papillomavirus Conference (2009 May), Malmö, Sweden 8-14 Abstract O01-07
17. An introduction to immunobiology and innate immunity. Chapter 1. In: Clancy J. (Ed). Basic concepts in immunology (2001), Garland Science, London
18. Dias D., Van Doren J., Schlottmann S., Kelly S., Puchalski D., Ruiz W., et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 12 (2005) 959-969
19. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus type 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
20. Smith J.F., Kowalski R., Esser M.T., Brown M.J., and Bryan J.T. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin 4 (2008) 134-142
21. Fleury M.J., Touzé A., Alvarez E., Carpentier G., Clavel C., Vautherot J.F., et al. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol 151 (2006) 1511-1523
22. Geijersstam V., Kibur M., Wang Z., Koskela P., Pukkala E., Schiller J., et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 177 (1998) 1710-1714
23. Lanzavecchia A., and Sallusto F. Human B cell memory. Curr Opin Immunol 21 (2009) 298-304
24. Schitteck B., and Rajewski K. Maintenance of B-cell memory by long lived cells generated from proliferating precursors. Nature 246 (1990) 749-751
25. Crotty S., and Ahmed R. Immunological memory in humans. Semin Immunol 16 (2004) 197-203
26. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007) 4931-4939